Is Visa Inc (V) Headed A Strong Growth Ahead Or Is It Facing A Decline?

In the CNBC‘s ‘Mad Dash,’ Jim Cramer shared his views on Visa Inc (NYSE:V). Cramer said that Charles W. Scharf, the CEO of Visa Inc (NYSE:V), is a brilliant man and that there is no doubt about it, but he added that the recent quarterly earnings release of the company was not in line with the market expectations.

Visa Inc (NYSE:V)

According to Cramer, even if Visa Inc (NYSE:V) has performed better than last quarter it still has performed below the mark and has highlighted the strengthening of the U.S. dollar as one of the major reasons that impacted its net operating revenues.

Cramer said that whenever the stock has got a hammer (fallen in price), it is time to buy it, but he also expressed his concerns, saying “It’s a very tough quarter to get your arms around, let the stock come in and then pick it up. Because the conference call made me feel less certain than I think, Charlie wanted us to feel.”

Meanwhile, as part of its earnings release for the second quarter 2014, Visa Inc (NYSE:V) reported a 26% raise in net income at $1.6 billion compared to $1.27 billion during the same period last year. The company also posted a 7% increase in revenue to $3.16 billion, compared to $2.96 billion for the same period in 2013, but the growth in revenue was lower than the market estimate of $3.19 billion.

The company also reduced its revenue growth forecast for the year 2014 to a range of 10% to 11% compared to the earlier forecast of 10% to 13% range. Byron Pollitt, the EVP and CFO of Visa Inc (NYSE:V) attributed the above change in forecast to the downward shift in the U.S. debit spending. As a result, following the earnings release the stock fell around 4%.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!